Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1040 participants.
Also called NCT05834868
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,040 participants
- Sponsor
- Tonghua Dongbao Pharmaceutical Co.,Ltd
- Registry
-
NCT05834868
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05834868. Randomized; no masking; primary purpose treatment. Start 2022-05-06 (actual); primary completion 2024-12-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- THDB0206 Injection
- Intervention (Drug)
- Insulin Lispro Injection
- Lead sponsor
- Tonghua Dongbao Pharmaceutical Co.,Ltd
Record details
- Record id
cardio:ct-nct05834868- Content hash
70bfb55d57e3daf88b7665a676906b1e6bd4c887f9b90df240eb4292ef8a3a59